TABLE 2.
Costs and health outcomes for AML patients
| Treatment | Total cost (SGD) | Effectivenessa |
ICER |
||||
|---|---|---|---|---|---|---|---|
| No. of IFIs | No. of IFIs avoided | LY | LY saved | Per IFI avoided | Per LY saved | ||
| Fluconazole | 4,186.91 | 0.100 | 5.197 | ||||
| Itraconazole capsule | 5,748.09 | 0.135 | −0.035 | 5.134 | −0.063 | Dominated | Dominated |
| Itraconazole solution | 4,172.47 | 0.066 | 0.034 | 5.258 | 0.061 | Dominant | Dominant |
| Posaconazole | 4,909.45 | 0.037 | 0.063 | 5.310 | 0.113 | 11,469 | 6,394 |
| Voriconazole | 14,095.61 | 0.049 | 0.051 | 5.288 | 0.091 | 194,288 | 108,887 |
a
IFI, invasive fungal infection; LY, life-years; ICER, incremental cost-effectiveness ratio.